GlaxoSmithKline PLC
LSE:GSK
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 300
1 797.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one GSK stock under the Base Case scenario is 2 400.47 GBX. Compared to the current market price of 1 342 GBX, GlaxoSmithKline PLC is Undervalued by 44%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
GlaxoSmithKline PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for GSK cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
GlaxoSmithKline PLC (GSK) is a global healthcare giant rooted in extensive research and development, dedicated to improving the health and well-being of people around the world. Founded in 2000 through a merger of Glaxo Wellcome and SmithKline Beecham, GSK has built a diverse portfolio that spans pharmaceuticals, vaccines, and consumer healthcare. With a strong emphasis on innovation, GSK invests heavily in R&D, focusing on tackling significant health challenges such as infectious diseases, oncology, and respiratory ailments. The company’s robust pipeline showcases its commitment to advancing medical science, promising both potential breakthroughs for patients and lucrative prospects for inv...
GlaxoSmithKline PLC (GSK) is a global healthcare giant rooted in extensive research and development, dedicated to improving the health and well-being of people around the world. Founded in 2000 through a merger of Glaxo Wellcome and SmithKline Beecham, GSK has built a diverse portfolio that spans pharmaceuticals, vaccines, and consumer healthcare. With a strong emphasis on innovation, GSK invests heavily in R&D, focusing on tackling significant health challenges such as infectious diseases, oncology, and respiratory ailments. The company’s robust pipeline showcases its commitment to advancing medical science, promising both potential breakthroughs for patients and lucrative prospects for investors.
In recent years, GSK has taken strategic steps to simplify its business model, including the spin-off of its consumer healthcare segment into a separate entity. This maneuver has allowed GSK to concentrate on its core pharmaceutical and vaccine operations, optimizing its resources towards high-growth areas. As the world faces ongoing health crises and the demand for vaccines, particularly following the COVID-19 pandemic, GSK is well-positioned to capitalize on its innovation and solid market presence. For investors, GSK's balance sheet reflects a stable dividend, attractive growth prospects, and a commitment to sustainable practices, fostering confidence that it remains a compelling choice in the ever-evolving healthcare landscape.
GlaxoSmithKline PLC (GSK) operates through several core business segments, primarily focusing on pharmaceuticals, vaccines, and consumer healthcare products. Here’s a breakdown of these segments:
-
Pharmaceuticals:
- This segment focuses on the research, development, and commercialization of prescription medications. GSK has a strong portfolio of drugs covering various therapeutic areas, including respiratory diseases (like asthma and COPD), HIV, oncology, immuno-inflammation, and neurology. Notable products include Advair (asthma), Tivicay (HIV), and Shingrix (shingles).
-
Vaccines:
- GSK is one of the leading vaccine producers in the world. This segment encompasses vaccines for a variety of infectious diseases, including influenza, meningitis, and hepatitis. GSK’s vaccine portfolio includes established products like Boostrix (whooping cough) and Bexsero (meningococcal B), as well as newer formulations aimed at preventing diseases like COVID-19.
-
Consumer Healthcare:
- This segment, which was formerly known as GSK Consumer Healthcare, includes over-the-counter (OTC) products, oral health products, and dietary supplements. GSK offers a wide range of well-known brands such as Sensodyne (toothpaste), Panadol (pain relief), and Voltaren (topical pain relief). This segment was partially divested to focus more on prescription drugs and vaccines.
GSK has made strategic shifts in recent years, including focusing more on high-growth areas such as specialty pharmaceuticals and vaccines, while also investing significantly in research and development across these core segments. The company’s aim is to have an innovative pipeline that meets evolving health needs effectively. Additionally, its commitment to sustainability and access to medicines is becoming increasingly important to its business strategy.
GlaxoSmithKline PLC (GSK) has several unique competitive advantages that distinguish it from its rivals in the pharmaceutical and healthcare sectors:
-
Diverse Product Portfolio: GSK has a well-diversified product portfolio, spanning pharmaceuticals, vaccines, and consumer health products. This diversification allows the company to mitigate risks associated with reliance on any single product or market.
-
Strong R&D Capabilities: GSK invests significantly in research and development (R&D), which is critical for innovation in pharmaceuticals and vaccines. The company's focus on R&D helps it develop new drugs and vaccines that can offer better efficacy and safety profiles.
-
Leading Vaccine Manufacturer: GSK is one of the largest vaccine producers globally, with a strong presence in key therapeutic areas like infectious diseases. This gives it a competitive edge, particularly during public health emergencies, such as the COVID-19 pandemic.
-
Strategic Partnerships and Collaborations: GSK has formed numerous strategic alliances with other biotech and pharmaceutical companies, academic institutions, and public health organizations. These partnerships enhance its research capabilities and market reach.
-
Global Reach and Presence: GSK operates in numerous countries worldwide, providing it with a substantial global market presence. This geographic diversification helps mitigate risks tied to local market conditions.
-
Strong Brand Equity: GSK has built strong brand recognition and trust in its products, particularly in consumer healthcare. This brand equity attracts consumers and healthcare professionals, providing a competitive edge.
-
Focus on Sustainable Practices: GSK's commitment to sustainability and corporate responsibility appeals to increasingly conscientious consumers and investors, distinguishing it from competitors that may not prioritize these initiatives.
-
Cost Efficiency and Operational Excellence: GSK's focus on operational excellence and cost management enables it to maintain healthy profit margins, allowing it to reinvest in R&D and marketing.
-
Regulatory Expertise: GSK’s extensive experience in navigating complex regulatory environments helps it bring products to market more efficiently than some of its rivals.
-
Innovative Business Models: GSK has been adapting its business models to meet changing market needs, such as a shift towards personalized medicine and digital health solutions, which enhances its competitive position.
By leveraging these competitive advantages, GlaxoSmithKline can maintain a strong position in the highly competitive pharmaceutical and healthcare industries.
GlaxoSmithKline PLC (GSK) faces several risks and challenges that could impact its business in the near future:
-
Patent Expiry and Generic Competition: As key patents expire, GSK may face increased competition from generic drug manufacturers, which could significantly reduce revenue from certain products.
-
Regulatory Challenges: The pharmaceutical industry is heavily regulated. Changes in regulations or delays in the approval of new drugs can result in increased costs and lost revenues.
-
Product Liability and Litigation: GSK, like other pharmaceutical companies, could face lawsuits related to product safety, efficacy, or marketing practices, leading to potential financial liabilities and reputational damage.
-
Market Competition: Competition from other pharmaceutical companies and emerging biotech firms is intense. Successful products from competitors can erode GSK’s market share.
-
Research and Development Risks: The pharmaceutical industry requires substantial investment in R&D, and there is always a risk that new drugs may fail during clinical trials, leading to wasted resources and lost opportunities.
-
Supply Chain Disruptions: Global events, such as the COVID-19 pandemic or geopolitical tensions, may disrupt supply chains and affect the availability of raw materials required for drug production.
-
Pricing Pressure: Increasing scrutiny on drug pricing from governments and insurers may impact GSK's pricing strategies and profitability, especially in markets focused on reducing healthcare costs.
-
Economic Conditions: Economic downturns can restrict healthcare budgets and affect sales of pharmaceuticals; this risk is especially pertinent in emerging markets.
-
Talent Acquisition and Retention: Attracting and retaining skilled professionals is crucial for innovation and success in R&D. A competitive job market can make this challenging.
-
Evolving Consumer Preferences: In the wake of the pandemic, there may be shifts in how consumers perceive and use healthcare products, potentially impacting demand for certain therapies.
-
Emerging Therapies and Technological Advances: Rapid advancements in biotechnology, genomics, and personalized medicine may require GSK to continuously innovate and adapt its product offerings to stay relevant.
-
Global Health Trends: Changes in disease prevalence, such as the rise of antibiotic resistance or chronic diseases, may influence GSK's product pipeline and market strategies.
Addressing these risks will require strategic planning, effective risk management, and continuous innovation to adapt to the changing business landscape in the pharmaceutical sector.
Revenue & Expenses Breakdown
GlaxoSmithKline PLC
Balance Sheet Decomposition
GlaxoSmithKline PLC
Current Assets | 16.8B |
Cash & Short-Term Investments | 3B |
Receivables | 7.8B |
Other Current Assets | 6B |
Non-Current Assets | 41.3B |
Long-Term Investments | 1.2B |
PP&E | 9.8B |
Intangibles | 22.4B |
Other Non-Current Assets | 7.9B |
Current Liabilities | 20.3B |
Accounts Payable | 14.2B |
Other Current Liabilities | 6.1B |
Non-Current Liabilities | 23.3B |
Long-Term Debt | 13.6B |
Other Non-Current Liabilities | 9.8B |
Earnings Waterfall
GlaxoSmithKline PLC
Revenue
|
31.4B
GBP
|
Cost of Revenue
|
-8.5B
GBP
|
Gross Profit
|
22.9B
GBP
|
Operating Expenses
|
-15.3B
GBP
|
Operating Income
|
7.6B
GBP
|
Other Expenses
|
-3.6B
GBP
|
Net Income
|
4B
GBP
|
Free Cash Flow Analysis
GlaxoSmithKline PLC
GBP | |
Free Cash Flow | GBP |
GSK's recent earnings call highlighted a solid performance, with Q3 sales growing 2% to GBP 8 billion and year-to-date growth at 9%. The Specialty Medicines segment drove growth, soaring 19%. Core operating profit and EPS increased 5%, despite a significant charge from Zantac litigation. For 2024, GSK maintains a sales growth guidance of 7% to 9% and profit growth of 11% to 13%. While vaccine sales sagged 15% amid shifting market conditions, robust prospects in oncology and respiratory treatments buoyed optimism. Consequently, cash from operations improved to GBP 5.3 billion, supporting future investments and an increased dividend, reinforcing GSK's focus on sustainable growth and shareholder returns.
What is Earnings Call?
GSK Profitability Score
Profitability Due Diligence
GlaxoSmithKline PLC's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
Score
GlaxoSmithKline PLC's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
GSK Solvency Score
Solvency Due Diligence
GlaxoSmithKline PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
GlaxoSmithKline PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GSK Price Targets Summary
GlaxoSmithKline PLC
According to Wall Street analysts, the average 1-year price target for GSK is 1 743.66 GBX with a low forecast of 1 363.5 GBX and a high forecast of 2 740.5 GBX.
Dividends
Current shareholder yield for GSK is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 90,096 full-time employees. The firm researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency virus (HIV), immuno-inflammation and oncology. Its Vaccines business has a portfolio of vaccines to help protect people from a range of diseases throughout their lives. Its vaccines tackle diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Its Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands that consumers trust, and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.
Contact
IPO
Employees
Officers
The intrinsic value of one GSK stock under the Base Case scenario is 2 400.47 GBX.
Compared to the current market price of 1 342 GBX, GlaxoSmithKline PLC is Undervalued by 44%.